Longeveron announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants will have an exercise price $1.62 per share, will become exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance. The offering is expected to close on or about December 26, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LGVN:
- Longeveron announces new clinical, biomarker results from Phase 2a CLEAR MIND
- Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
- Longeveron initiated with a Buy at H.C. Wainwright
- Longeveron files to sell 5.02M shares of Class A common stock for holders
- Longeveron presents long-term survival data from ELPIS 1 trial